Apalutamide

Generic Name
Apalutamide
Brand Names
Erleada
Drug Type
Small Molecule
Chemical Formula
C21H15F4N5O2S
CAS Number
956104-40-8
Unique Ingredient Identifier
4T36H88UA7
Background

Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Ne...

Indication

Apalutamide is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.

Associated Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
Associated Therapies
Androgen Deprivation Therapy
Clinical Trials
Related News

Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People With Metastatic Castration Sensitive Prostate Cancer and Less Than Optimal PSA Response

First Posted Date
2024-09-19
Last Posted Date
2024-10-21
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
830
Registration Number
NCT06592924

Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study

First Posted Date
2024-05-28
Last Posted Date
2024-05-28
Lead Sponsor
Medical University of Vienna
Target Recruit Count
500
Registration Number
NCT06430411

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial

First Posted Date
2024-04-23
Last Posted Date
2024-11-26
Lead Sponsor
Mayo Clinic
Target Recruit Count
120
Registration Number
NCT06378866
Locations
🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

First Posted Date
2024-03-20
Last Posted Date
2024-08-09
Lead Sponsor
University College, London
Target Recruit Count
8000
Registration Number
NCT06320067
Locations
🇬🇧

University College London Hospitals NHS Foundation Trust, London, United Kingdom

🇬🇧

The Royal Marsden Hospital, Sutton, United Kingdom

🇬🇧

Royal Devon University Hospital Trust, Exeter, United Kingdom

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

First Posted Date
2024-02-23
Last Posted Date
2024-11-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
120
Registration Number
NCT06274047
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States

First Posted Date
2024-01-12
Last Posted Date
2024-04-09
Lead Sponsor
Bayer
Target Recruit Count
1800
Registration Number
NCT06204302
Locations
🇺🇸

Bayer, Whippany, New Jersey, United States

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients with Prostate Cancer, HEATWAVE Trial

First Posted Date
2023-10-04
Last Posted Date
2024-10-09
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
95
Registration Number
NCT06067269
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings

First Posted Date
2023-08-28
Last Posted Date
2024-06-26
Lead Sponsor
Bayer
Target Recruit Count
1375
Registration Number
NCT06013475
Locations
🇺🇸

Bayer, Whippany, New Jersey, United States

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

First Posted Date
2023-07-27
Last Posted Date
2024-07-19
Lead Sponsor
University of Washington
Target Recruit Count
34
Registration Number
NCT05960578
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

First Posted Date
2023-06-13
Last Posted Date
2024-12-05
Lead Sponsor
Janssen-Cilag Ltd.
Target Recruit Count
450
Registration Number
NCT05901649
Locations
🇩🇪

Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, Germany

🇦🇹

Klinikum Wels Grieskirchen, Wels, Austria

🇦🇹

Akh Wien, Wien, Austria

and more 45 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy